That means Libtayo has a chance to build a position as a go-to immunotherapy in cervical cancer, which is the fourth most commonly occurring cancer in women with around 500,000 cases worldwide ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

as well as in advanced cervical cancer in many countries. Regeneron is currently looking to expand its portfolio beyond Libtayo. Its oncology pipeline includes other candidates like linvoseltamab ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...